You are viewing a single comment's thread.

view the rest of the comments →

0
2

[–] derram 0 points 2 points (+2|-0) ago 

https://archive.fo/VjkjE :

“Is curing patients a sustainable business model?” Goldman Sachs analysts ask | Ars Technica

'For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. '

'In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. '

'The report noted that diseases such as common cancers—where the “incident pool remains stable”—are less risky for business. '

'While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow. '

'But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. '


This has been an automated message.